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Abstract Glioblastoma multiforme (GBM) is the most aggressive human primary brain cancer.
Using a Trp53-deficient mouse model of GBM, we show that genetic inactivation of the Atm
cofactor Atmin, which is dispensable for embryonic and adult neural development, strongly
suppresses GBM formation. Mechanistically, expression of several GBM-associated genes, including
Pdgfra, was normalized by Atmin deletion in the Trp53-null background. Pharmacological ATM
inhibition also reduced Pdgfra expression, and reduced the proliferation of Trp53-deficient primary
glioma cells from murine and human tumors, while normal neural stem cells were unaffected.
Analysis of GBM datasets showed that PDGFRA expression is also significantly increased in human
TP53-mutant compared with TP53-wild-type tumors. Moreover, combined treatment with ATM and
PDGFRA inhibitors efficiently killed TP53-mutant primary human GBM cells, but not untransformed
neural stem cells. These results reveal a new requirement for ATMIN-dependent ATM signaling in
TP53-deficient GBM, indicating a pro-tumorigenic role for ATM in the context of these tumors.
DOI: 10.7554/eLife.08711.001
Introduction
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain cancer in
adults. Despite improvements in clinical care, a rapid disease progression and insufficient under-
standing of the etiology of these tumors results in very poor survival prognosis. The standard treat-
ment for GBM patients involves a combination of the DNA damaging agent temozolomide together
with radiotherapy (Stupp et al., 2005). However, the benefits of current treatment regimes come
with severe side effects for patients, as well as drug resistance and inevitable recurrence of the
tumor (Wen and Kesari, 2008).
Over recent years, great efforts by individual research groups and consortia have shed light on
the key genetic events that lie at the heart of human GBM formation, raising the possibility of a
more targeted approach to therapy. This has identified activation of growth factor receptor signaling
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(for example by amplification or overexpression of the PDGF receptor) and direct or indirect inacti-
vation of the TP53 and retinoblastoma tumor suppressors as core deregulated pathways in human
GBM (Cancer Genome Atlas Research Network, 2008). Unfortunately, many of these pathways are
difficult to target pharmacologically in vivo, and for others, like PDGFR signaling, available inhibitors
have so far lacked clinical impact (Wen et al., 2006; Rich et al., 2004). Hence, an important goal of
GBM research is to identify novel, more effective therapies to generate better outcomes.
One of the central determinants of tumor progression and the response to therapy is the DNA
damage response (Lord and Ashworth, 2012). The DNA damage kinase ATM is known primarily as
a tumor suppressor, through its role in the response to DNA double-strand breaks (Shiloh and Ziv,
2013), and systemic loss of ATM has previously been shown to accelerate glioblastoma progression
(Squatrito et al., 2010). This tumor suppressive role is in line with the activation of the DNA damage
response in precancerous lesions as a barrier to tumorigenesis (Bartkova et al., 2005). A recent
study has, however, demonstrated loss of ATM signaling to inhibit the growth of TP53-null tumor
xenografts, via stabilization of p14ARF (Velimezi et al., 2013), suggesting that ATM function in can-
cer is highly context-dependent.
As well as its canonical activation at break sites, ATM signaling also occurs in response to other
cellular stresses (Bakkenist and Kastan, 2003), and this mode of ATM signaling requires the ATM
INteractor ATMIN (Kanu and Behrens, 2007). ATMIN interacts with the ATM kinase in basal condi-
tions and disassociates from ATM in response to ionizing radiation, to allow ATM to interact with
the MRN complex at double-strand break sites (Zhang et al., 2014). ATMIN also has ATM-indepen-
dent functions, most notably the transcriptional activation of Dynll1, a motor protein involved with
ciliogenesis and crucial for lung development (Jurado et al., 2012a; Goggolidou et al., 2014). In
addition, ATMIN has been shown to counteract oxidative damage in the brain (Kanu et al., 2010)
and to protect against B cell lymphomagenesis (Loizou et al., 2011), but its role in other cancer
types has not yet been determined.
A key downstream mediator of the DNA damage response pathway, activated by both the dou-
ble-strand break and ATMIN-dependent responses, is the tumor suppressor TP53. Precancerous
lesions in which the DNA damage response is activated are under selective pressure to lose or
mutate TP53, and loss of TP53 is known to cooperate with several genes to accelerate tumorigenesis
(as summarized in the IARC database [Petitjean et al., 2007]). Among these cooperating changes is
loss of ATM, which induces rapid T-cell lymphoma development (Westphal et al., 1997). TP53 is
also one of the most commonly mutated genes in human GBM. Consequently, the majority of avail-
able mouse models of GBM use deletion of one or both copies of the Trp53 gene in combination
eLife digest Glioblastomas are the most common and aggressive brain cancers in adults, and
currently lack efficient treatment options. Glioblastoma cells contain genetic mutations that enable
them to grow and divide more quickly than they would under normal conditions. The occurrence of
these mutations often leads to a functional impairment in so-called ’tumor suppressor’ proteins that
may have a range of roles, including repairing genetic damage or controlling the rate of cell division.
Blake et al. have now studied how some of these tumor suppressor proteins interact. Deleting a
prominent tumor suppressor called TP53 from the brain of mice caused these animals to develop
glioblastomas. If, however, both TP53 and another tumor suppressor called ATMIN were deleted at
the same time, the majority of mice did not develop any brain tumors. Further in-depth profiling of
these brain tumor cells revealed that TP53-deleted cells had very high levels of the oncogene
PDGFRA, which causes cells to divide more rapidly. These high PDGFRA levels were brought back
to normal conditions upon deletion of ATMIN.
Blake et al. then studied primary human glioblastoma cells that lack TP53 and found that these
cells could be efficiently killed by a combination of drugs that block the activity of PDGFRA and the
protein ATM, which is known to work in concert with ATMIN. Importantly, this combination of drugs
did not adversely affect healthy brain cells, opening up new strategies and potential treatment
options for glioblastoma patients.
DOI: 10.7554/eLife.08711.002
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with other mutations (Chen et al., 2012). Overexpression of the Pdgf receptor ligand Pdgfrb in adult
Nestin-positive neural stem cells, for instance, results in glioma formation, which is accelerated in a
Trp53-mutant background (Squatrito et al., 2010).
In this study, we demonstrate that congenital loss of Trp53 in the mouse brain is sufficient to pre-
cipitate spontaneous glioblastoma formation, and that this correlates with upregulation of Pdgfra.
Further, we show that ATMIN plays a critical role in GBM formation, promoting Pdgfra protein and
gene expression in a Trp53-deficient background, using an in vivo glioma model as well as neural
stem cell and primary tumor cell cultures. Importantly, we find that these results are translatable to
therapeutic ATM inhibition in human patient-derived GBM stem cells, and that combining ATM inhi-
bition with PDGFRA inhibition results in synergistic tumor cell killing with minimal effects on untrans-
formed cells.
Results
Glioblastomas develop at high frequency in p53DN (Trp53 mutant) mice
Loss of TP53 is one of the earliest occurring events in human GBM initiation (Maher et al., 2001;
Wang et al., 2009; Ohgaki et al., 2004; Mazor et al., 2015; Johnson et al., 2014). This inevitably
results in the accumulation of a plethora of secondary hits, which, after a long latency period, leads
to tumor formation. To recapitulate this chain of events in mice, we deleted Trp53 as an initial driver
during neural development (using p53f/f; Nestin-Cre (p53DN) mice) and monitored brain tumor for-
mation in late adult life. After 8 months, brain tumors arose in p53DN mice with high penetrance
(Figure 1A and B), similar to previous observations using an hGFAP-Cre model (Wang et al., 2009).
Animals began to show neurological symptoms including reduced movements and tremor at an
average age of 263 days. When examined histologically, many p53DN tumors had features consistent
with WHO classification criteria for Grade IV GBM (Figure 1C). Out of 17 animals, 14 (82%) showed
diffusely infiltrative astrocytic brain tumors, the majority of which were classified as GBM by indepen-
dent analysis (57% Grade IV, glioblastoma; 29% Grade III, anaplastic astrocytoma; 14% Grade II,
fibrillary astrocytoma), while one displayed an osteosarcoma (Figure 1B and D, Figure 1—figure
supplement 1 and Supplementary file 1). p53DN GBMs displayed pseudopalisading necrosis (i),
microvascular proliferation with endothelial hyperplasia (ii) and occasional endovascular thrombosis
(iii), hallmarks of human GBM tumors (Figure 1E [i–iii]). The markers Gfap (iv), Nestin (v), and Olig2
(vi) were expressed in all tumors, while they were negative for the neuronal marker NeuN, support-
ing the diagnosis of glioma (Figure 1E (iv–vi) and Figure 1—figure supplement 2). Intertumoral and
intratumoral heterogeneity, a classic hallmark of high-grade gliomas, was also frequently observed
(Figure 1F). These data indicate that early embryonic loss of Trp53 in the brain is sufficient to pro-
mote GBM formation. The long latency of these tumors, together with the genome instability and
transcriptional changes known to be induced by loss of Trp53, indicated that these gliomas almost
certainly develop as a result of secondary mutations arising in the Trp53-null brain. In line with this
notion, mouse SNP array data revealed large chromosomal gains and losses (typical tumorigenic
genetic changes) in four out of five analyzed p53DNgliomas, whereas no changes were detected in
one wt and three Trp53-deficient non-tumorigenic control NS cells (Figure 1—figure supplement
3). These secondary hits are not congenitally predefined and thus possibly allow a better representa-
tion of the genetic diversity of the disease in patients. In addition, the high frequency of brain tumor
formation, proportion of high-grade tumors, and consistency of tumor latency on a mixed genetic
background make this a valuable GBM model.
Loss of Atmin strongly suppresses GBM formation in the p53DN model
As an integral part of the response to genomic stress, activation of the DNA damage response path-
way typically represents a barrier to tumorigenesis. Consistent with this, it has previously been
shown that loss of the DNA damage kinase Atm accelerates tumorigenesis in a Pdgf-driven glioblas-
toma model (Squatrito et al., 2010). In addition, deletion of the Atm cofactor Atmin promotes B
cell lymphomagenesis (Loizou et al., 2011). Whether loss of Atmin affects tumorigenesis in other
cancer types is so far unknown. To investigate the potential role of Atmin in glioma formation, we
crossed AtminDN mice (Kanu et al., 2010) with p53DN mice. Strikingly, AtminDN; p53DN mice showed
significantly longer tumor-free survival than p53DNanimals (p<0.0002) (Figure 2A). The largest
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Figure 1. Loss of Trp53 is sufficient to induce GBM with high penetrance. (A) Kaplan-Meier curves showing tumor-free survival in p53f/f; Nestin-Cre
(p53DN) and control Nestin-Cre mice. (B) Status of mouse cohorts at 450 days, showing tumor incidence. (C) H&E-stained p53DN brain tumor sections
showing histological features of malignant GBM. Arrowheads indicate (i) a mitotic cell, (ii) neo-vascularization, (iii) rosetta formation, (iv) mitotic
catastrophe, (v) a multinucleated giant cell, and (vi) large areas of necrosis. (D) Grades of gliomas for p53DN mice. (E) Examples of human GBM
hallmarks observed in p53DN tumors: pseudopalisading necrosis (i), microvascular proliferation with endothelial hyperplasia (ii), and endovascular
thrombosis (iii) (all H&E). Immunohistochemistry shows expression of the glial markers GFAP (iv), NESTIN (v), and OLIG2 (vi) in p53DN tumors. (F) p53DN
glioblastomas display high inter- and intra-tumoral heterogeneity. H&E images i-ii, iii-iv, and v-vi represent different regions of the same tumors #1, #2,
and #3 respectively. GBM, Glioblastoma multiforme.
DOI: 10.7554/eLife.08711.003
Figure 1 continued on next page
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proportion of AtminDN; p53DNmice (43%) did not develop any signs of sickness and were still alive
after 450 days; a further 36% succumbed either to non-tumor-related illness or, in one case, a pan-
creatic tumor (Figure 2B and Supplementary file 1). Only three animals out of a cohort of 14
AtminDN; p53DNdouble mutants (21%) initiated glial tumors (Figure 2B), compared with 82% of
p53DNmice over the same period. The three GBMs arising in AtminDN; p53DNdouble-mutant mice
arose later but were histologically similar to those observed in p53DN mice (Figure 2—figure supple-
ment 1), and did not escape Atmin deletion, suggesting that the requirement for Atmin can eventu-
ally be overcome, but only in a small proportion of cases. Importantly, central nervous system
deletion of Atmin alone (AtminDN) did not affect brain morphology or histology (Kanu et al., 2010)
and the mice remained tumor free (Figure 2A). Thus, Atmin deletion strongly suppresses GBM for-
mation in p53DN animals.
Atmin loss rescues hyperproliferation and sensitivity to hypoxia in
p53DNNSCs
Loss of Trp53 affects diverse fundamental cellular processes including proliferation, genome stabil-
ity, cell cycle arrest, and apoptosis (Vousden and Lane, 2007). To understand the involvement of
Atmin in the suppression of the Trp53-null phenotype, we isolated neural stem cells (NSCs) (Fig-
ure 2—figure supplement 2) from p53DNembryos and tested the effect of Atmin loss on these pro-
cesses. p53DNNSCs proliferated more rapidly than wild-type (wt) controls. This proliferative
advantage, however, was rescued in AtminDN; p53DN NSCs (Figure 2C and D), indicating that Atmin
is required for the hyperproliferation of Trp53-deficient NSCs. Loss of Atmin alone did not alter pro-
liferation of NSCs (Figure 2—figure supplement 3). FACS profiling of p53DN and AtminDN; p53DN
NSCs revealed a decrease in the proportion of AtminDN; p53DN cells in S phase compared with
p53DN NSCs, in agreement with the reduced proliferation rate, but no change in cells with a >4n
DNA content, and metaphase spreads at passage 10 revealed no obvious difference in ploidy (Fig-
ure 2—figure supplement 4). We analyzed cell cycle arrest and cell death in response to ionizing
radiation (IR) by quantifying the percentage of BrdU-incorporating and DAPI-permeable NSCs
respectively. As expected, p53DN NSCs arrested less efficiently than wt NSCs and cell death was
reduced; but cell cycle arrest and cell death were not rescued in AtminDN; p53DN NSCs (Figure 2E
and Figure 2—figure supplement 5). In addition to IR-induced cell death, p53DN NSCs were more
resilient to hypoxia-induced death, consistent with previous studies (Liu et al., 2007; Graeber et al.,
1996). Atmin deletion in these cells re-sensitized them to hypoxia, to similar levels as wt NSCs
(Figure 2F). Thus, loss of Atmin is able to rescue some of the phenotypes of Trp53 loss, such as
hyperproliferation and hypoxia induced death, but not others, such as IR-induced cell cycle arrest
and cell death.
Loss of Atmin impairs the tumorigenicity of neural stem cells in
orthotopic transplants
As increased proliferation and hypoxia resistance are attributes commonly found in tumor initiating
cells of solid tumors, including glioma (Graeber et al., 1996; Gilbertson and Rich, 2007), we evalu-
ated the tumorigenic potential of p53DN and AtminDN; p53DN NSCs in vivo. We performed intracra-
nial injections of NSCs isolated from wt, p53DN, and AtminDN; p53DNembryos (Figure 2G). Five out
of five animals injected with p53DN NSCs died within 93 days post-injection, while four out of five wt
and three out of four p53DN; AtminDNNSC-injected animals were still alive even at 155 days, the
Figure 1 continued
The following figure supplements are available for figure 1:
Figure supplement 1. Histological features of lower grade tumors observed in p53DN animals.
DOI: 10.7554/eLife.08711.004
Figure supplement 2. Histological features of glioblastomas observed in p53DN animals.
DOI: 10.7554/eLife.08711.005
Figure supplement 3. SNP array analysis on primary cells derived from GBM bearing p53DN, non-tumor bearing p53DN , and wild-type (wt) animals.
DOI: 10.7554/eLife.08711.006
Figure supplement 4. Table representing CGHcall output for SNP array analysis compressed to comparable regions between arrays in the series.
DOI: 10.7554/eLife.08711.007
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endpoint of the experiment (Figure 2G). Histologically, injected cells appeared as atypical glial cells
expressing Nestin and Ki67, diffusely infiltrating the host brain (Figure 2—figure supplement 6),
similar to previous observations with human GBM xenografts (Stricker et al., 2013). Fluorescent
imaging of asymptomatic mice at the experimental endpoint readily detected injected AtminDN;
p53DN and wt NSCs (Figure 2—figure supplement 7), suggesting that these cells survived in the
host brain, but did not induce lethality. Thus, genetic inactivation of Atmin greatly impairs the tumor-
igenic potential of p53DNcells.
Atmin loss normalizes expression of the proto- oncogene Pdgfra in
p53DN NSCs
To understand the molecular basis of the observed attenuation of tumorigenic potential, we per-
formed gene expression profiling on wt, p53DN, and AtminDN; p53DNembryonic NSCs. Compared
with wt NSCs, 145 genes were downregulated more than 1.5-fold in p53DN, whereas 77 were over-
expressed (Figure 3A). Many of the canonical Trp53 target genes, such as Bax, Puma, and Cdkn1a,
were downregulated to a similar extent in AtminDN; p53DN compared with p53DNNSCs. However,
27% of genes deregulated in p53DNNSCs returned to wt expression levels when Atmin was also
deleted (36/145 of the decreased, and 24/77 of the increased genes; examples in Figure 3B). When
this subset of genes ‘rescued’ in double mutant NSCs was queried against the Cancer Genome Atlas
(TCGA) database, in several cases abnormal levels of these transcripts were found to be associated
with human GBM (Cancer Genome Atlas Research Network, 2008; Suvasini et al., 2011). Particu-
larly notable among this list was the platelet-derived growth factor receptor alpha (Pdgfra)
(Figure 3C). Elevated levels of PDGFRA have been observed in human gliomas of various malig-
nancy grades (Engstro¨m et al., 2012), and increased PDGFR signaling has been shown to induce gli-
oma-like growths in vivo (Jackson et al., 2006). Increased PDGFRA levels are also a characteristic
hallmark of the proneural GBM subtype as classified in (Brennan et al., 2013; Verhaak et al., 2010).
Interestingly, we found that p53DNNSCs were associated most closely with the proneural subtype
when comparing the microarray expression profile from the murine NSCs to that of publically avail-
able human GBM samples from TCGA (Verhaak et al., 2010) (Figure 3—figure supplement 1),
which is in agreement with elevated Pdgfra mRNA as well as protein levels (Figure 3D). This
increased protein expression was also apparent in high-grade GBMs from endstage p53DNanimals
(Figure 3E and Figure 3—figure supplement 2). Other growth factor receptors, like Egfr, and pro-
teins commonly deregulated in glioma including Rb, Pten, Cyclin D2, Junc, and Cdk4 (Wang et al.,
2009) remained unaltered in p53DNcells and tumors (Figure 3—figure supplements 2 and 3), as did
the closely related Pdgf receptor Pdgfrb and the receptor ligands Pdgfa and Pdgfb (Figure 3—fig-
ure supplement 4).
Importantly, deletion of Atmin together with Trp53 completely rescued the elevated Pdgfra
expression, reducing it to wild-type levels (Figure 3C and D). Overexpression of tagged Atmin in
double mutant NSCs restored elevated Pdgfra expression at both the mRNA and protein levels
(Figure 3F and G), while acute silencing of Atmin in p53DNNSCs, using two independent shRNA con-
structs, reduced Pdgfra levels (Figure 3H), implying that sustained Pdgfra upregulation in
p53DNNSCs constantly requires Atmin function to maintain increased Pdgfra expression. Thus, inter-
ference with Atmin function is sufficient to reduce Pdgfra overexpression in Trp53-deficient cells.
To assess whether Trp53 null tumors require sustained Pdgfra overexpression, we isolated pri-
mary tumor cells from GBM-bearing p53DNmice and induced stable knockdown of Pdgfra using
shRNA (Figure 3—figure supplement 5). This resulted in a significant decrease in the proliferation
rate of these primary tumor cells (Figure 3I), emphasizing the importance of Atmin function in sup-
porting elevated Pdgfra expression in p53DNgliomas.
Pdgfra overexpression is reversible with pharmacological Atm
inhibition
Atmin has two known functions: an Atm-dependent function, in which Atmin interacts with Atm and
is required for Atm signaling in several stress contexts, and an Atm-independent function, in which
Atmin is required for transcription of the dynein light chain Dynll1. To determine whether acute
silencing of Atmin in tumor cells might reduce Pdgfra expression by disrupting Atm signaling, we
tested the effects of pharmacological Atm inhibition in p53DNprimary tumor cells. Treatment with an
Blake et al. eLife 2016;5:e08711. DOI: 10.7554/eLife.08711 6 of 24
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Figure 2. Loss of Atmin rescues GBM formation in p53DN brains. (A) Kaplan-Meier curves showing tumor-free survival in AtminDN and AtminDN; p53DN
mice. p53DN curve from Figure 1A (same experiment) is shown for comparison. (B) Status of mouse cohorts at 450 days, showing tumor incidence. (C)
Atmin loss rescues the increased proliferation of p53DN NSCs. (D) Mean percentage of BrdU-positive NSCs from the indicated genotypes, assessed by
FACS following a 2-hr BrdU pulse. (E) Mean number of DAPI-permeable (non-viable) cells after IR or (F) hypoxia, showing sensitivity of AtminDN; p53DN
NSCs to hypoxia but not IR. n.s., not significant; * p<0.05, ** p<0.01. (G) Scheme of orthotopic NSC transplant experiment (left) and Kaplan-Meier
curves indicating survival of NOD/SCID mice orthotopically transplanted with p53DN and AtminDN; p53DN NSCs (right). Error bars represent the SEM of
three biological repeats, and two biological repeats for (E). IR, Ionizing radiation; NSC, Neural stem cell.
DOI: 10.7554/eLife.08711.008
Figure 2 continued on next page
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Atm inhibitor (ATMi) significantly reduced Pdgfra transcript and protein levels (Figure 4A and B)
and efficiently reduced proliferation of p53DNprimary tumor cells (Figure 4C), similar to our observa-
tions after Pdgfra silencing. ATMi treatment also reduced Pdgfra expression in p53DNNSCs
(Figure 4D and Figure 4—figure supplement 1). Consistent with these results, Atm-/-;
p53DNdouble-mutant NSCs had dramatically lower Pdgfra expression levels than p53DNNSCs, com-
parable to AtminDN; p53DNand wt NSCs (Figure 4E and F). Furthermore, in vitro proliferation assays
showed that genetic loss of Atm reduced the proliferation of p53DNNSCs to wt levels (Figure 4G).
Importantly, the reduction in cell proliferation in vitro correlated with reduced tumorigenic potential
of the NSCs when orthotopically injected into the brains of NOD/SCID mice. Mice injected with
Atm-/-; p53DNNSCs survived up to 50% longer than those receiving p53DNNSCs (Figure 4H). How-
ever, Atmin deletion (Figure 2G) was more effective than deletion of Atm (Figure 4H). Atmin can
also act as a transcription factor (Jurado et al., 2012a; 2012b; Goggolidou et al., 2014), and it is
conceivable that this Atm-independent function of Atmin contributes to the suppression on GBM.
The similar effect of Atmin deletion and Atm inhibition on Pdgfra expression and proliferation of
NSCs and primary tumor cells supports the hypothesis that Atmin functions in these processes via its
modulation of Atm signaling. Given the extensively characterized role of PDGFRA in cell proliferation
and in particular in glioma, it is reasonable to propose that the reduction in Pdgfra expression upon
Atm loss contributes to the reduced tumorigenic potential observed.
Since Atm is best known as a DNA damage signaling kinase, we examined whether the effect of
Atm on Pdgfra expression and tumorigenicity was related to altered DNA damage signaling in
p53DNglioma cells. Neither p53DNnor AtminDN; p53DNNSCs showed increased gh2ax or 53bp1 foci in
basal conditions (Figure 5A and B), suggesting that the different proliferation rates are not caused
by changes in endogenous DNA damage. Pdgfra expression was not affected by IR or hydroxyurea
(HU), two well-described inducers of ATM signaling, either in wt or in p53DNNSCs (Figure 5C) and
no increased Atm substrate phosphorylation could be detected in untreated p53DN NSCs
(Figure 5D), suggesting that Pdgfra upregulation is not a consequence of stimulation of DNA dam-
age signaling. Atm substrate phosphorylation was also comparable in IR- and HU-treated wt,
p53DNand AtminDN; p53DNNSCs (Figure 5D), suggesting that the response to DNA damage stimuli
is comparable in these cells. This suggests that while Atm is required for the increased Pdgfra
expression in p53DN cells, this does not involve alterations in IR or HU-induced Atm signaling, but at
this point does not exclude the possibility that increased ROS (reactive oxygen species) levels in
p53DN GBM cells might contribute to Atm pathway activation and subsequent Pdgfra induction and
GBM development.
Primary human glioma neural stem cells are sensitive to ATM inhibition
and combinatorial treatment with PDGFR inhibitors
To investigate the relevance of ATM signaling for PDGFRA upregulation in human GBM, we took
advantage of patient derived human GBM neural stem cells (GNSCs) (Stricker et al., 2013) that
Figure 2 continued
The following figure supplements are available for figure 2:
Figure supplement 1. Histological features of glioblastomas observed in p53DN and AtminDN; p53DN animals.
DOI: 10.7554/eLife.08711.009
Figure supplement 2. Examples of murine neural stem cells in culture.
DOI: 10.7554/eLife.08711.010
Figure supplement 3. AtminDN NSCs proliferate at a similar rate as wild-type NSCs.
DOI: 10.7554/eLife.08711.011
Figure supplement 4. Gross genome stability is unaffected in Atmin/Trp53 double mutant NSCs.
DOI: 10.7554/eLife.08711.012
Figure supplement 5. Radiation-induced arrest is similarly impaired in Trp53-mutant and Atmin/Trp53 double mutant NSCs.
DOI: 10.7554/eLife.08711.013
Figure supplement 6. Tumors arising from orthotopic injection of NSCs are Nestin and Ki67-positive.
DOI: 10.7554/eLife.08711.014
Figure supplement 7. Asymptomatic AtminDN; p53DN-injected animals show persistent GFP-positive cells.
DOI: 10.7554/eLife.08711.015
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Figure 3. Atmin regulates Pdgfra expression in a mutant Trp53 background. (A) Heatmap showing genes deregulated more than 1.5-fold in Trp53 null
NSCs and their corresponding expression in AtminDN; p53DN double null NSCs. (B, C) qRT-PCR validation of GBM implicated genes that show
deregulated expression in p53DN but not AtminDN; p53DN NSCs. (D) Elevated Pdgfra protein expression in p53DN but not AtminDN; p53DN NSCs.
Corresponding p-Akt and total Akt levels were probed to analyze pathway activation. Actin was used as loading control. (E) Tumor section from a GBM
arising from a p53DN animal showing elevated Pdgfra expression. ’N’ denotes the normal brain region adjacent to the tumor mass. Dotted lines
indicate tumor border. (F) Myc-Atmin overexpression increases expression of Pdgfra mRNA in AtminDN; p53DN but not wt cells. (G) Myc-Atmin
overexpression increases Pdgfra protein levels in AtminDN; p53DN NSCs. Tubulin was used as loading control. (H) Atmin silencing using two
independent shRNA constructs reduces Pdgfra expression, assessed by qRT-PCR. (I) Stable Pdgfra silencing using two independent shRNA constructs
Figure 3 continued on next page
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have documented TP53 mutations (lines G26, G166, and G179, Figure 6A). We confirmed that cell
extracts from each of these human tumors were unable to activate a luciferase construct containing
multiple TP53-binding elements (Figure 6—figure supplement 1). PDGFRA expression was signifi-
cantly increased in two out of three human GNSC lines compared with untransformed human neural
stem cells (cb660; (Engstro¨m et al., 2012; Pollard et al., 2009) (Figure 6B). To assess whether this
observation is representative of the wider human GBM spectrum, we analyzed the gene expression
patterns in the ’Glioblastoma Multiforme (TCGA, provisional)’ dataset from The Cancer Genome
Atlas. We analyzed 153 RNA-seq and 500 microarray datasets for 518 glioblastoma samples and
completed these with the clinical subgroup information from (Brennan et al., 2013). The gene
expression datasets contained z-scores representing the differences in expression levels of PDGFRA
between cancer and control samples (Figure 6—figure supplements 2 and 3). The RNA-seq and
microarray data were handled separately; for each, we observed higher average PDGFRA expression
in TP53-mutant glioblastoma samples compared with TP53 wild-type samples (Figure 6C,D). We
also observed higher PDGFRA expression levels in the Proneural and GCiMP GBM subtypes when
compared to the Classical, Neural, and Mesenchymal (Figure 6E and Figure 6—figure supplement
4).
In line with the data from our mouse model, treatment with an ATMi strongly reduced PDGFRA
expression in GNSCs, whereas no significant effect on PDGFRA expression was detected in cb660
controls (Figure 6F). To determine whether a reduction in PDGFRA levels would be sufficient to
inhibit the proliferation of primary GNSCs from human tumors, G179 cells were infected with doxy-
cycline (dox)-inducible shRNA constructs targeting PDGFRA (Figure 6G and Figure 6—figure sup-
plement 5), and their proliferation was monitored over a period of 10 days. In agreement with our
results in the mouse, depletion of PDGFRA led to a significant decrease in the proliferation rate of
human GNSCs (Figure 6H). Thus, both murine and human TP53-mutant glioma cells are sensitive to
loss of PDGFRA.
To analyze the physiological effects of ATM inhibition on GNSCs, proliferation was monitored
over a period of 7 days. Similar to our observations in murine NSCs, ATMi treatment reduced the
proliferation rate of human TP53 mutant GNSCs, but not cb660 control cells (Figure 7A). PDGFR
inhibitors (PDGFRi) have previously been shown in vitro and in vivo to reduce tumor growth in a gli-
oma model (Kilic et al., 2000). These advances, however, have so far failed to transition into clinical
practice (Wen et al., 2006; Rich et al., 2004). We reasoned that ATMi-mediated reduction in
PDGFRA protein levels could potentiate the effects of PDGFR inhibition. Consistent with this, we
observed that co-treatment of GNSCs, but not untransformed NSCs (e.g. cb660), with relevant ATM
and PDGFR inhibitor concentrations further reduced cell proliferation (Figure 7A and Figure 7—fig-
ure supplement 1). More detailed analysis revealed that this treatment combination induced sub-
stantial cell death, while untransformed NSCs remained largely unaffected (Figure 7B,C). The
Figure 3 continued
reduces primary tumor cell proliferation, measured using IncuCyte timelapse microscopy. Error bars represent the SEM of at least three biological
repeats and two biological repeats in (I).* p<0.05, ** p<0.01, *** p<0.001. NSC, Neural stem cell
DOI: 10.7554/eLife.08711.016
The following figure supplements are available for figure 3:
Figure supplement 1. The transcriptional profile of p53DN NSCs is most closely related to the human proneural GBM subtype, relative to expected
distances.
DOI: 10.7554/eLife.08711.017
Figure supplement 2. Pdgfra expression is elevated in p53DNtumors, but Egfr is not.
DOI: 10.7554/eLife.08711.018
Figure supplement 3. Some markers frequently altered in GBM are unaltered in p53DN NSCs.
DOI: 10.7554/eLife.08711.019
Figure supplement 4. Pdgf ligand expression is not significantly altered in p53DN NSCs.
DOI: 10.7554/eLife.08711.020
Figure supplement 5. Two independent shRNAs cause Pdgfra knockdown.
DOI: 10.7554/eLife.08711.021
Figure supplement 6. miR34a expression is reduced in p53DN NSCs.
DOI: 10.7554/eLife.08711.022
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Figure 4. Atm inhibition reduces Pdgfra expression and reduces tumorigenic potential in murine p53DN primary tumor cells and NSCs. (A–B) Atm
inhibitor (ATMi) treatment reduces Pdgfra protein levels (A) and Pdgfra expression (B) in p53DN primary tumor cells. (C) ATMi treatment reduces in vitro
proliferation of p53DN primary tumor cells. Error bars represent the SEM of two biological repeats. (D) ATMi reduces Pdgfra expression in p53DN NSCs,
assayed by qPCR. (E–F) Pdgfra expression (E) and Pdgfra protein levels (F) are reduced in Atm-/-; p53DN and AtminDN; p53DN compared with p53DN
NSCs. cDNA is normalized to Actin levels. Error bars represent the SEM of at least three biological repeats. s.e. and l.e. denote short and long
exposures of the same blot, respectively. (G) Genetic loss of Atm reduces in vitro proliferation of p53DN NSCs. Error bars represent the SEM of two
biological repeats. (H) Kaplan-Meier curves indicating increased survival of NOD/SCID mice orthotopically transplanted with Atm-/-; p53DN NSCs
compared with p53DN NSCs. n.s., not significant; * p<0.05, ** p<0.01, *** p<0.001. NSC, Neural stem cell.
DOI: 10.7554/eLife.08711.023
The following figure supplement is available for figure 4:
Figure supplement 1. ATM inhibitor (ATMi) treatment reduces Pdgfra protein levels in p53DN NSCs. NSCs, Neural stem cells.
DOI: 10.7554/eLife.08711.024
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Figure 5. Atm signaling in response to DNA damaging agents is remarkably unaffected in p53DN and AtminDN;
p53DN cells and DNA damaging treatments do not affect Pdgfra expression. (A) p53DN and AtminDN; p53DN NSCs
do not show elevated gh2ax and 53bp1 foci in untreated conditions, suggesting low endogenous damage. Cells
treated with 5Gy IR (wt +IR) are shown as a positive control. (B) Quantification of gh2ax and 53bp1 foci in (A). Error
bars indicate 95% confidence intervals. (C) qPCR of Pdgfra in wt and p53DN NSCs in untreated conditions and after
DNA damage-inducing stimuli. cDNA is normalized to Actin levels. Error bars represent SEM of three biological
repeats. (D) Western blots depicting Atm substrate phosphorylation after the indicated stimuli in NSCs of different
genotypes.
DOI: 10.7554/eLife.08711.025
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Figure 6. ATM inhibitor treatment reduces elevated PDGFRA expression and decreases proliferation in human
GBM tumor cells. (A) Mutational status of TP53, PTEN, IDH1, and EGFR in the indicated glioma neural stem stell
(GNSC) lines. n.e., not expressed. wt, wild type. (B) Western blot depicting PDGFRA, TP53, PTEN, and ACTIN
expression in three GNSC lines (G26, G166, and G179) and cb660 control cells. (C,D) Box plots showing PDGFRA
expression in TP53-wt and TP53-mutant TCGA human glioblastoma datasets, measured by microarray (n=153). (C)
or RNA-Seq (n=500). (D) Data from 518 patient samples in total with an overlap of 135 patients. (E) Box plots
showing PDGFRA expression z-scores in TCGA human glioblastoma subtypes, measured by RNA-Seq (n=150). p-
Values in (C–E) calculated using Wilcoxon’s test. (F) qRT-PCR showing decreased PDGFRA expression in TP53-
mutant GNSC lines after ATM inhibitor (ATMi) treatment. cDNA is normalized to GAPDH levels. Error bars
represent the STDEV of two biological repeats. (G) Western blot showing knockdown of PDGFRA using a
doxycycline (Dox)-inducible shRNA construct. (H) PDGFRA knockdown using doxycycline (Dox)-inducible shRNA
reduces proliferation of TP53-mutant G179 GNSCs. Cell confluence measured by IncuCyte timelapse microscopy.
Error bars represent the SEM of three biological repeats. * p<0.05, *** p<0.001, n.s., not significant.
DOI: 10.7554/eLife.08711.026
Figure 6 continued on next page
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proportion of apoptotic GNSCs receiving the combination treatment was quantifiable by micro-
scopic detection of a caspase-cleaved fluorescent substrate after up to four days of drug treatment;
thereafter, dead cells detached from the plate, precluding accurate quantification. Essentially, all
GNSCs were eventually killed by the combination of ATM and PDGFR inhibitors, as judged by cell
detachment. In contrast, PDGFRi treatment by itself had little effect on cell death and proliferation
(Figure 7 A–C). Seeding GNSCs at higher confluence gave similar results (Figure 7—figure supple-
ment 2), as did a second, independent PDGFRi in combination with the ATMi (Figure 7—figure sup-
plement 3), indicating that cell death was not an indirect consequence of slower proliferation
induced by the ATMi or a side effect of a particular drug. Hence, ATM is required for PDGFRA over-
expression in both murine and human GBM cells, and combined inhibition of ATM and PDGFR indu-
ces lethality in TP53-mutant glioma cells, promising new opportunities for future GBM treatment.
Our data indicate that disruption of Atm/Atmin function not only inhibits GBM initiation in Trp53-
deficient animals, but also reduces the tumorigenic potential of established human glioma cells, sug-
gesting that ATM inhibitors might be valuable tools in GBM therapy.
Discussion
An important goal of personalized cancer medicine is to identify vulnerabilities of specific tumor
genotypes. Since TP53 signaling is the most common genetically altered pathway in human gliomas
(Cancer Genome Atlas Research Network, 2008), it is desirable for future cancer therapies to iden-
tify new molecular targets that affect TP53-deficient cells. Here, we have shown that genetic loss of
Atmin or Atm reduces GBM formation initiated by deletion of Trp53. This finding indicates that
Atm/Atmin is crucial for Trp53-deficient GBM development, and suggests the use of ATM inhibitors,
which have already been developed, for GBM therapy (Basu et al., 2012; Golding et al., 2009;
2012; Batey et al., 2013).
Although other groups have previously observed that loss of Trp53 is sufficient to provoke GBM
formation (Wang et al., 2009; Zheng et al., 2008), the potential advantages of this model system
have largely been overlooked. Even on a mixed genetic background, mice harboring a Nestin-driven
Trp53 deletion show strong consistency in tumor latency, high penetrance of brain tumors and high-
grade GBM formation. Such a model, incorporating the stochastic evolution and genetic heteroge-
neity of human glioblastoma patients, complements existing genetically defined mouse models that
show an accelerated disease course (Chen et al., 2012).
Atm is a rare example of a protein required for formation of a Trp53-deficient tumor that is ame-
nable to pharmacological inhibition, with potential direct therapeutic implications. This pro-tumori-
genic function for Atmin and Atm signaling in brain cancer is unexpected, as systemic Atm deletion
has previously been found to accelerate Pdgf ligand-induced gliomagenesis (Squatrito et al., 2010).
However, the previous study was carried out in Trp53 wild-type animals. It was recently shown that
Figure 6 continued
The following figure supplements are available for figure 6:
Figure supplement 1. Luciferase reporter assay for TP53 activity using the p53-550RE construct in human GNSC
(G26, G166, G179) and control NSC (cb660) lines. NSC, Neural stem cell.
DOI: 10.7554/eLife.08711.027
Figure supplement 2. Correlation of PDGFRA expression levels in TCGA glioblastoma samples represented in
both microarray and RNASeq datasets.
DOI: 10.7554/eLife.08711.028
Figure supplement 3. Comparison of the distribution of PDGFRA expression levels in human glioblastoma
samples measured by RNASeq and by microarray.
DOI: 10.7554/eLife.08711.029
Figure supplement 4. Box plots showing PDGFRA expression z-scores in TCGA human glioblastoma subtypes
measured by microarray (n=487).
DOI: 10.7554/eLife.08711.030
Figure supplement 5. Control for Figure 6G and H showing efficient knockdown of PDGFRA after doxycycline
administration.
DOI: 10.7554/eLife.08711.031
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Figure 7. Combinatorial treatment with both ATM and PDGFR inhibitors induces apoptosis of human glioma stem
cells. (A) Growth curves showing the proliferation of wild-type control human neural stem cells (cb660) and two
independent cell lines isolated from TP53-deficient human gliomas (G166 & G179) over 7 days in the presence of
vehicle control (DMSO), ATM inhibitor (ATMi), PDGFR inhibitor (PDGFRi), or both inhibitors. Error bars depict
STDEV from two biological repeats. (B) Representative bright-field/fluorescent images of the same cell types
treated as above after 4 days. Cells undergoing apoptosis are labeled by emitting GFP. (C) Quantification of
apoptotic cells after the treatments indicated above, represented as % apoptotic cells from total live cells. Error
bars depict STDEV from three biological repeats. After four days, it became impossible to quantify apoptotic
GNSCs receiving the combination treatment, since they detached completely from the culture plate. These
percentages thus represent an underestimate of the total extent of G166 and G179 cell death with ATMi +
PDGFRi.
DOI: 10.7554/eLife.08711.032
The following figure supplements are available for figure 7:
Figure 7 continued on next page
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TP53 status is crucial in determining the cellular response to ATM inhibition in human glioma cell
lines (Biddlestone-Thorpe et al., 2013), so this difference might explain the apparently opposite
function of Atm in our model. TCGA data indicates that ATM mutation/deletion is rare in TP53-
mutant GBM, supporting the hypothesis that ATM loss is not a tumor driver and may even inhibit
tumorigenesis in this context. Because the pleiotropic effects of ATM signaling are highly context
dependent, factors other than TP53 status must also influence the outcome in vivo. For example,
loss of Atm cooperates with Trp53 deficiency and accelerates the progression of T-cell lymphoma
(Westphal et al., 1997). Thus, the relationship between TP53 and ATM signaling in tumorigenesis
may be tissue specific, ranging from cooperation to antagonism.
Adding to this context dependency, ATM’s function in the DNA damage response inhibits tumor-
igenesis in precancerous lesions but can also promote resistance to DNA damaging therapies in
established tumors. Indeed, recently published work has shown that ATM inhibition preferentially
radiosensitizes TP53 mutant GBM cell lines (Biddlestone-Thorpe et al., 2013). Our data reveal an
additional pro-tumorigenic effect of Atm, which acts in the absence of ionizing radiation and involves
non-canonical, Atmin-dependent signaling. It is possible that the effect of Atm inhibition in our
model would also be enhanced by ionizing radiation, since the radiosensitizing effect would be pre-
dicted to be largely independent of Atmin (Kanu and Behrens, 2007). Thus, combination treatment
with ATM and PDGFR inhibitors together with radiotherapy may represent a therapeutic opportunity
for GBM.
Our results indicate that the requirement for the Atm/Atmin pathway in p53DN GBM lies in the ini-
tiation of a program of altered gene expression (Figure 3A) and does not directly involve the DNA
damage response to double-strand breaks induced by IR or HU (Figure 5B and C). Although Atmin
has been implicated directly as a transcription factor for Dynll1 (Jurado et al., 2012b), a broader
role for Atmin in transcriptional regulation had not yet been determined. We find here that Atmin
loss leads to widespread rescue of glioma-associated changes in gene expression in the p53DN back-
ground. Several of these genes could be collectively responsible for suppressing GBM formation in
Atmin
DN
; p53DN animals. The most compelling single candidate, however, is the proto-oncogene
Pdgfra. It has been shown that stimulating Pdgf signaling in vivo is sufficient to induce glioma-like
growths (Jackson et al., 2006). Moreover, PDGFRA is commonly overexpressed in human glioma
(Engstro¨m et al., 2012), but only a subset of gliomas display PDGFRA locus amplification
(Furnari et al., 2007) (Cancer Genome Atlas Research Network, 2008), indicating that additional
mechanisms drive its increased expression. PDGFRA overexpression frequently correlates with LOH
on chromosome 17p, where the human TP53 gene is located (Hermanson et al., 1996), supporting
the view that the oncogenic misexpression of PDGFRA might be a direct consequence of TP53 inac-
tivation in human GBM. In our murine and human glioma lines, Pdgfra levels could be dynamically
modulated by depleting Atmin or inhibiting Atm. At present, how Atm/Atmin controls Pdgfra
expression in this background is unclear. Chromatin immunoprecipitation experiments in murine
NSCs indicated that Atmin does not bind the Pdgfra gene (unpublished observations), making the
regulation unlikely to be via direct transactivation, most likely involving currently unidentified inter-
mediate transcriptional regulators of Pdgfra expression. We speculate that Trp53 controls the
expression of a negative regulator of Pdgfra, for example, a repressor or a miR RNA, and that Atm
signalling is required for the expression or function of this factor. As these intermediate factors could
be promising targets for pharmacological inhibition, further investigation into their identity is of ther-
apeutic interest.
Although the oncogenic role of PDGFR signaling in glioma is well established, the clinical efficacy
of PDGFR inhibitors has so far been disappointing (Wen et al., 2006; Rich et al., 2004). Here, we
Figure 7 continued
Figure supplement 1. ATM and PDGFR inhibitors were used at minimally required concentration to achieve
pathway inhibition.
DOI: 10.7554/eLife.08711.033
Figure supplement 2. Bright-field images of timelapse microscopy using cells seeded at high confluency.
DOI: 10.7554/eLife.08711.034
Figure supplement 3. Apoptosis quantification of a second PDGFR inhibitor.
DOI: 10.7554/eLife.08711.035
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demonstrate that the effect of these drugs on the proliferation and survival of human glioma cells
can be greatly potentiated by combining PDGFR inhibitor treatment with ATM inhibitors. Impor-
tantly, the strongest effects of combinatorial treatment on cell proliferation and survival are specific
to tumor cells that have lost TP53 function, suggesting that systemic therapy should target TP53-
deficient tumors with minimal impairment to normal tissue.
A second encouraging result of combining ATM and PDGFRA inhibitors is that they not only
reduce tumor cell proliferation, but also potently induce cell death. While our data support coopera-
tion based on simultaneous inhibition of PDGFR signaling at the transcriptional and protein kinase
levels, it is likely that this synergy also encompasses broader effects of ATM and PDGFRA inhibition.
In addition, current PDGFR inhibitors are not completely specific and also inhibit EGFR, VEGFR,
FLT3, and c-KIT kinases amongst others (Andrae et al., 2008; Homsi and Daud, 2007). Similarly,
ATM inhibitors have also been shown to display broader kinase inhibitor activity, especially at higher
concentrations (Hickson et al., 2004). Thus, PDGFR-independent mechanisms could contribute to
the observed treatment synergy.
In summary, we have identified a novel protumorigenic function of ATM signaling in GBM. Our
results present a rationale for expanding the investigation of ATM inhibitors from radiosensitizers to
potential therapies in their own right, and point toward improvements in the efficacy of PDGFRA
inhibition using combination treatment.
Materials and methods
Ethics statement
Experiments in mice were carried out with the approval of the Crick Institute’s Ethical Review Com-
mittee and under the guidance of the Biological Resources Unit.
Animal models
Atminf/f, p53f/f, Atm-/-, and Nestin-Cre mice have been described previously (Kanu et al., 2010;
Jonkers et al., 2001; Barlow et al., 1996; Tronche et al., 1999). Immunocompromised NOD/SCID
mice were maintained in-house. Mice were maintained and bred on a mixed background in patho-
gen-free conditions, monitored for signs of ill health and culled when moribund. Strain background
had no significant effect on the latency or development of gliomas in p53DNmice.
Cell culture
NSCs were isolated as spheres from fore and midbrains of mouse E13.5 embryos. Cells were initially
cultured as spheres under self-renewal conditions, as previously described. Adherent NSC cultures
were derived as previously described (Pollard et al., 2006; Conti et al., 2005) with minor modifica-
tions (Sancho et al., 2013). Briefly, primary spheres were plated in Neurobasal Medium
(Invitrogen, Grand Island, NY, USA) supplemented with 1% Penicillin/Streptomycin (Invitrogen), 1%
L-glutamine (Invitrogen), 2% B27 supplement (Invitrogen), 1% N-2 supplement (Invitrogen), 20 ng/ml
EGF (PeproTech), 20 ng/ml FGF-basic (PeproTech), and 1 mg/ml laminin (Sigma). All experiments
were performed using undifferentiated adherent NSCs (see Figure 2—figure supplement 2).
Primary tumor cells were generated from brain tumor samples of symptomatic mice (Figure 3—
figure supplement 5). Tissue was subjected to mechanical and enzymatic dissociation, and single
cells initially cultured to form spheres. Tumor spheres formed were then maintained as adherent
tumor cell cultures in NSC media as described above.
Plasmids and reagents
pCMV6-myc-ATMIN was generated by cloning mouse Atmin into a pCMV6 backbone. Silencing and
mismatch constructs for Atmin have been described previously (Kanu and Behrens, 2007). The lucif-
erase p53 response element (pGL3-550RE) was kindly provided by Karen Vousden. The ATM inhibi-
tor Ku55993 (Merck) was used at 10 mM and replenished every 24 hr.
For DNA damage induction, NSCs of the indicated genotypes were either left untreated or sub-
jected to 0.8 Gy irradiation or 2 mM hydroxyurea (HU) and harvested after 1 hr and 3 hr respectively
for RNA extraction or protein lysates.
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Transfection and luciferase assay
For transfection, NSCs and GNSCs were plated at subconfluence and transfected with Lipofectamine
2000 according to the manufacturer’s protocol (Invitrogen).
For luciferase assays, samples were transiently transfected with Firefly and Renilla luciferase
reporters and luciferase activity was measured using the Dual-Luciferase Reporter Assay System
(Promega), 36-hr post-transfection. Data are expressed as fold induction of luciferase activity after
being normalized to expression of thymidine kinase-renilla luciferase (TK-renilla).
Western blots and immunoprecipitation
For Western Blots (WB), NSCs were extracted in RIPA lysis buffer (NEB) supplemented with protease
inhibitors (Sigma). For immunoprecipitation (IP) cells were lysed in IP buffer (20mM sodium phos-
phate buffer, 1 mM EDTA, 0.2% NP40, 150 mM NaCl supplemented with Na-orthovanadate, PMSF,
NaF and protease inhibitor mixture [Sigma]). After sonication and centrifugation, supernatant was
incubated overnight at 4˚C with PDGFRA antibody, followed by 2-hr incubation with Dynabeads M-
280 (Invitrogen), washed with IP buffer (0 mM NaCl, 150 mM NaCl and 1 M NaCl) and eluted in
Laemmli sample buffer. All primary antibodies were used at 1:1000 dilution and secondary antibod-
ies at 1:10000. The following antibodies were used: p53, Pdgfra, p-Pdgfra, p-Chk2, p-Akt, Akt (all
Cell Signaling); Myc-9E10 (CRUK); Smc1 (Abcam); p-Smc1, Chk2, Tubulin (all Merck); p-Kap1, Kap1
(both Bethyl Labs); Atm (Santa Cruz), p-Atm (Epitomics), p-p53, Actin, GAPDH, HRP-conjugated
goat anti-mouse/rabbit IgG (all Sigma).
Quantitative RT-PCR
For qRT-PCR analysis, mRNA was isolated from NSCs using the RNeasy mini kit (Qiagen). Results
(normalized to Actin expression) are presented as fold change relative to control. Sequences of pri-
mers used are listed in Supplementary file 2.
Cell proliferation and hypoxia assays
For cell proliferation assays, NSCs were plated in duplicate in 12-well plates and cell number mea-
sured every day using a ViCell cell counter. The initial number of cells seeded was used to normalize
to 100%. Mean averages were taken from at least four independent lines per genotype taken from
different embryos and crosses. For BrdU profiling, cells pulsed with BrdU for 2 hr were fixed in 70%
ethanol, stained with BrdU antibody and propidium iodide (PI) and analyzed by flow cytometry.
For hypoxia assay, NSCs were seeded in duplicate into 6-well plates and next day placed into a
hypoxic chamber at 0.1% O2 for 72 hr. ATM inhibitor was replenished after 24 hr and 48 hr. For cell
death analysis, control-treated and hypoxia-treated cells were subjected to DAPI staining and ana-
lyzed via flow cytometry. Mean averages were taken from at least three independent experiments.
IR-induced death and arrest
To determine IR-induced death, NSCs were irradiated at 5Gy and after 24 hr incubated with 4’-6-
Diamidino-2-phenylindole (DAPI; Sigma) and assessed for apoptosis via flow cytometry. G1/S phase
arrest was assessed by irradiating NSCs at 5Gy and after 18 hr pulsing with BrdU for 1.5 hr. Cells
were prepared for flow cytometry as described above and gated on BrdU-positive cells. Mean aver-
ages were taken from at least three independent experiments.
Orthotopic transplants
1x105 early passage (p.4) GFP labeled NSCs of the indicated genotypes were injected using a ste-
reotaxic frame into the striatum of 6- to 8-week-old mice (NOD/SCID strain), following administra-
tion of general anaesthesia as previously described. Animals were monitored daily and culled when
moribund.
Human NS and GNS cell culture
Fetal NS cell lines and GNS lines derived from human glioma samples have been described previ-
ously (Stricker et al., 2013; Pollard et al., 2009). The same culture conditions apply as previously
described for mouse NSCs. Cell proliferation was measured over a period of four or seven days
using an incubator microscope system for live cell imaging and measurement of cell confluence over
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several days (IncuCyte) and cell death was quantified using CellPlayer Caspase 3/7 Reagent from
Essen Bioscience. Cells were seeded at 1.2x104 or 2.4x104 into a 48-well plate and images taken
every 30 min. The ATM inhibitor KU55993 was added at 10 mM. PDGFR inhibitors III and V (CAS
205254-94-0 and CAS 347155-76-4 respectively, both Merck) were used at 1mM and replenished
every 24 hr over a period of four or seven days as indicated. Stable shPDGFRA GNSC lines were
generated by viral infection of GNSCs with pTRIPZ-shPDGFRA targeting and control vectors
(Thermo Fisher). Doxycycline was added at a final concentration of 0.5 mg/ml and replenished every
day.
Histological analysis and tumor grading
All mice were euthanized in a CO2 chamber to preserve brain tissue. Brain sections were cut at 4 mm
for Hematoxylin & Eosin (H&E) staining and all antibody staining. The following antibodies were
used for IHC: Nestin (BD Bioscience), Gfap (Dako), Olig2, Neun (both Merck), Synaptophysin
(Sigma), Pdgfra (Cell Signaling), Ki67 (Abcam). Tumor grading was determined on the basis of the
WHO grading system for malignant astrocytoma.
Microarray analysis
Three independent NSC lines from each indicated genotype were pooled and submitted for
genome wide gene expression profiling using the Illumina Mouse ref 8 v3.0 expression bead chip.
Raw data were processed using the ’lumi’ package (Du et al., 2008) within Bioconductor
(Gentleman et al., 2004) first by applying the variance-stabilizing transform, and then carrying out
quantile normalization. Following this, genes were selected on the basis of a 1.5-fold threshold on
the mean of the technical duplicates (technical correlation being higher than 0.996 in all cases). The
microarray data depicted in Figure 3A has been uploaded to the GEO database under the accession
number GSE76296.
Using our normalised microarray data, we calculated the average log fold change between each
condition and the wild-type samples. We then calculated distance (following the procedure of [Dab-
ney, 2006]) of these expression profiles to the centroids of the four GBM subtypes identified in
(Verhaak et al., 2010). We mapped the expression profile from mouse to human by matching up
gene names between the two species, resulting in a correspondence for 674 of the 840 genes in the
GBM signature. To assess informally the specificity of the subtypes, and to gain some insight into
the strength of the similarities to GBM subtypes, we bootstrapped the log fold changes within sam-
ples 1000 times, recording the pairwise distances between bootstrapped samples and fixed GBM
subtype-centroids.
Copy number variation calling
Total genomic DNA was extracted and purified using DNeasy Blood & Tissue Kit (Qiagen). Copy
number variation (CNV) detection was performed using the Affymetrix Mouse Diversity Genotyping
Array (MDGA) at AROS Applied Biotechnology. Genotypes were called from the CEL files using the
BRLMM-P algorithm in Affymetrix Power Tools (APT) (available from: http://www.affymetrix.com/
estore/partners_programs/programs/developer/tools/powertools.affx) using default settings, includ-
ing quantile normalization. PennAffy (available from: http://penncnv.openbioinformatics.org/en/lat-
est/user-guide/download/) was implemented to generate Log R Ratio (LRR) and B-allele frequency
(BAF) using canonical genotype clustering and population frequency of the B-allele (PFB) files kindly
provided by Locke et al. (Locke et al., 2015). Markers that do not probe allelic balance (exon
markers in the MDGA) were removed. GC content was calculated for 1 Mb windows centred by
each marker using BEDTools (Quinlan and Hall, 2010). LRR was then corrected for genomic wavi-
ness by subtracting the median normalised GC content multiplied by a coefficient optimised to gen-
erate the minimum variance when subtracted from the LRR. Copy number states were then called
for mouse autosomes using the ‘CGHcall’ R package (van de Wiel et al., 2007) in Bioconductor
(Gentleman et al., 2004) using the ’sdundo’ option for the undo.splits parameter for segmentation.
Only CNVs larger than 1 Mb were reported.
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TCGA data analysis
Gene expression measurements were obtained by downloading the ’Glioblastoma Multiforme
(TCGA, provisional)’ dataset using the cBioPortal (http://www.cbioportal.org/, version 05/09/2014)
for The Cancer Genome Atlas (http://cancergenome.nih.gov/). The dataset contained 500 microar-
rays and 153 RNA-seq measurements for 518 glioblastoma patients. Glioblastoma expression sub-
group information was obtained from (Brennan et al., 2013), and gene expression levels were
represented as z-scores. The RNA-seq and microarray data were analyzed separately but the z-
scores for PDGFRA are correlated across 135 samples for which both data types are available
(Spearman correlation coefficient = 0.85 for 135 samples with both RNA-seq and microarray data,
Figure 6—figure supplement 2), indicating that the two measurement types are comparable. Differ-
ences in expression z-scores between TP53 mutant and TP53 wt status, as well as glioblastoma sub-
groups (combining GCiMP and Proneural versus Neural, Classical, and Mesenchymal) were tested
using the Wilcoxon’s test. Three outlier points from each of the TP53 wt and mutant groups in
Figure 6D, as well as six outlier points (5 Proneural and 1 Mesenchymal) in Figure 6E are excluded
from the plot for clarity.
Statistical analysis
Tumor-free survival was analyzed using GraphPad Prism 6 and statistical analyses to determine
tumor-free survival were performed using the Mantel-Cox test. For TCGA data analysis p values
were determined using the Wilcoxon’s test. For all other experiments with error bars, the unpaired
Student’s t-test was performed to determine statistical significance.
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